Back to Search
Start Over
Clinical Characteristics and Antimicrobial Susceptibility Trends inCitrobacterBacteremia: An 11-Year Single-Center Experience
- Source :
- Infection & Chemotherapy. 51:1
- Publication Year :
- 2019
- Publisher :
- Korean Society of Infectious Diseases and Korean Society for Chemotherapy, 2019.
-
Abstract
- Background Recently, Citrobacter freundii bacteremia outbreak in a neonatal intensive care unit has attracted public attention in Korea. However, Citrobacter bacteremia is uncommon and usually occurs in patients with underlying diseases such as malignancy and hepatobiliary diseases. Increase in resistance and emerging of multidrug resistance among Citrobacter species have gradually been reported. The aim of this study was to investigate the clinical characteristics and outcome of C. freundii and non-freundii bacteremia and antimicrobial susceptibility trends. Materials and methods We reviewed the medical records of patients with Citrobacter bacteremia at St. Mary's Hospital, from 2007 to 2017. Results A total of 43 patients with a median age of 72 (24-93) years was identified and 90.7% of them had comorbidities. Twenty-nine (67.4%) patients had C. freundii bacteremia while 14 had non-freundii bacteremia (six of C. braakii, five of C. koseri, two of C. amalonaticus and one of C. youngae). A total of 26 (51.2%) patients had community-acquired infection and intra-abdominal infection including hepatobiliary tract was the most common portal of entry (24/43, 55.8%). Moreover, hepatobiliary tract was the leading primary site of nosocomial infection (9/17, 52.9%). Polymicrobial bacteremia was observed in 21 (48.8%) patients. The percentages of Citrobacter species susceptible to ampicillin, amikacin, aztreonam, cefazolin, cefoxitin, cefotaxime, cefepime, piperacillin-tazobactam, ciprofloxacin, and imipenem were 9.5%, 97.6%, 73.8%, 9.5%, 14.3%, 71.4%, 92.9%, 83.3%, 83.3% and 100%, respectively. The resistance rate did not increase during the study period. Of 39 patients treated with antibiotics, 36 (92.3%) received appropriate empirical antibiotics. Overall mortality was 18.6%. High Charlson comorbidity index and Pitt bacteremia score were significant risk factors for death in univariate analysis and showed trends in the multivariate analysis. No significant difference in clinical features and antimicrobial susceptibility rate was observed between C. freundii and non-freundii bacteremia. Conclusion Citrobacter bacteremia was predominant in the elderly with comorbidities, while no pediatric case was observed. Hepatobiliary tract is the leading primary focus of bacteremia both in community-acquired and nosocomial infection. The rate of susceptibility to antibiotics has not changed in the last 11 years.
- Subjects :
- Citrobacter
0303 health sciences
medicine.medical_specialty
Imipenem
biology
030306 microbiology
business.industry
Cefepime
Drug resistance
bacterial infections and mycoses
biology.organism_classification
medicine.disease
Citrobacter freundii
03 medical and health sciences
0302 clinical medicine
Infectious Diseases
Amikacin
Internal medicine
Ampicillin
Bacteremia
Medicine
Pharmacology (medical)
030212 general & internal medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 20926448 and 20932340
- Volume :
- 51
- Database :
- OpenAIRE
- Journal :
- Infection & Chemotherapy
- Accession number :
- edsair.doi...........7a1f908553504a5046791955dee6d924
- Full Text :
- https://doi.org/10.3947/ic.2019.51.1.1